Medicines
One profile per molecule. Brands, formulations and dose arms sit inside the molecule's profile, so Wegovy, Ozempic and Rybelsus are all semaglutide, and Mounjaro and Zepbound are both tirzepatide. Each profile shows regulatory status by jurisdiction with authorisation, launch and funded access kept separate.
GLP-1 and amylin receptor agonist (single molecule) 路 Peptide
No brand yet
In developmentAmylin analogue plus GLP-1 receptor agonist (combination) 路 Peptide combination
No brand yet
Under regulatory reviewGLP-1 receptor agonist 路 Peptide (Fc fusion)
Brands: Trulicity
Approved somewhereAmylin receptor agonist 路 Peptide
No brand yet
In developmentGLP-1 receptor agonist 路 Peptide
Brands: Saxenda, Victoza
Approved somewhereGLP-1 and glucagon receptor agonist 路 Peptide
No brand yet
In developmentGLP-1 receptor agonist 路 Small molecule (non-peptide)
Brands: Foundayo
Approved somewhereGIP, GLP-1 and glucagon receptor agonist 路 Peptide
No brand yet
In developmentGLP-1 receptor agonist 路 Peptide
Brands: Wegovy, Ozempic, Rybelsus
Approved somewhereGIP and GLP-1 receptor agonist 路 Peptide
Brands: Zepbound, Mounjaro
Approved somewhere